ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT
Azeem, M., Naureen, H., Nasiri, M., Saleem, M. (2020). ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT. EKB Journal Management System, 43(1), 27-38. doi: 10.21608/bfsa.2020.93568
Muhammad Azeem; Humaira Naureen; Muhammad Iqbal Nasiri; Muhammad Umair Saleem. "ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT". EKB Journal Management System, 43, 1, 2020, 27-38. doi: 10.21608/bfsa.2020.93568
Azeem, M., Naureen, H., Nasiri, M., Saleem, M. (2020). 'ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT', EKB Journal Management System, 43(1), pp. 27-38. doi: 10.21608/bfsa.2020.93568
Azeem, M., Naureen, H., Nasiri, M., Saleem, M. ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT. EKB Journal Management System, 2020; 43(1): 27-38. doi: 10.21608/bfsa.2020.93568

ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT

Bulletin of Pharmaceutical Sciences Assiut University
Article 3, Volume 43, Issue 1, June 2020, Page 27-38  XML PDF (383.9 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2020.93568
View on SCiNiTO View on SCiNiTO
Authors
Muhammad Azeem1; Humaira Naureen2; Muhammad Iqbal Nasiri3; Muhammad Umair Saleem3
1Department of Pharmaceutics, Hamdard Institute of Pharmaceutical Sciences, Hamdard University Islamabad Campus, Pakistan & Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan
2Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan
3Department of Pharmaceutics, Hamdard Institute of Pharmaceutical Sciences, Hamdard University Islamabad Campus, Pakistan
Abstract
The objectives of the current study were to estimate the out-of-pocket costs of illness of blood culture-confirmed typhoid fever, as well as to evaluate the different brands of ciprofloxacin HCl used in the treatment of typhoid fever. Therefore, a comparative study was designed for the assessment of costs of treatment at sixteen public (Government sector) and private tertiary health care hospitals located in Rawalpindi and Islamabad, Pakistan. On the basis of prescriptions collected from the hospitals, seven different brands of ciprofloxacin HCl prescribed in the treatment of typhoid fever were purchased from retail pharmacies for quality assessment. The mean costs for fourteen days and seven days treatment were analyzed and the overall costs of treatment were high at private health care sectors than public sectors. Model independent approach like similarity factor (f2) was also applied to assess the similarity between the dissolution profiles of different brands, and result indicated that three brands were found to be similar with reference product, while, three were dissimilar. It can be concluded that this cost-effective analysis of antibiotics used in the typhoid fever, will help to the local regularity body as well as WHO to update typhoid fever immunization recommendations. Ciprofloxacin was found an effective antibacterial agent in the treatment of typhoid fever and all brands met the pharmaceutical quality parameters. Thus, physicians, pharmacists and patients can select most appropriate quality brand for the therapy of typhoid fever.
Statistics
Article View: 354
PDF Download: 399